← Evidence map

ArticleFrontiers in immunology2026

Case Report: Long-term survival of refractory high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements through glofitamab monotherapy consolidated by ASCT.

Fang Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Case Report: Long-term survival of refractory high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements through glofitamab monotherapy consolidated by ASCT. | OpenQuestion